Q4 Earnings Estimate for Repligen Issued By Leerink Partnrs

Repligen Corporation (NASDAQ:RGEN) – Equities research analysts at Leerink Partnrs increased their Q4 2025 earnings per share (EPS) estimates for Repligen in a research report issued to clients and investors on Wednesday, November 19th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will earn $0.45 per share for the quarter, up from their prior forecast of $0.44. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q1 2026 earnings at $0.45 EPS, Q2 2026 earnings at $0.49 EPS, Q4 2026 earnings at $0.60 EPS and FY2026 earnings at $2.10 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The firm had revenue of $188.81 million for the quarter, compared to the consensus estimate of $181.23 million. During the same quarter last year, the business posted $0.43 earnings per share. The firm’s revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS.

A number of other brokerages also recently commented on RGEN. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Evercore ISI raised their price target on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Repligen in a research report on Wednesday. Royal Bank Of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Tuesday, September 2nd. Finally, HSBC assumed coverage on Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Repligen Trading Up 5.3%

Shares of RGEN stock opened at $162.51 on Monday. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $102.96 and a twelve month high of $182.52. The company’s 50-day moving average price is $144.66 and its 200-day moving average price is $130.33. The stock has a market cap of $9.15 billion, a price-to-earnings ratio of 8,129.56, a PEG ratio of 3.32 and a beta of 1.15.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 25,000 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the transaction, the director owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. This represents a 19.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO James Bylund sold 2,191 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 49,382 shares of company stock worth $7,676,802 over the last 90 days. 1.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Twin Tree Management LP acquired a new position in shares of Repligen in the first quarter valued at approximately $29,000. Measured Wealth Private Client Group LLC purchased a new position in Repligen in the 3rd quarter valued at approximately $29,000. Hantz Financial Services Inc. boosted its position in Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares during the period. CWM LLC grew its stake in shares of Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. increased its position in shares of Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 126 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.